Clinical trial
A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis
NCT00617032 is registered in ClinicalTrials.gov with Targeted Genetics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis
- Lead sponsor
- Targeted Genetics Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 29, 2004
- Completion date
- November 30, 2005
- Enrollment
- 15 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis
Lead sponsor's other trials
Targeted Genetics Corporation, most recent start first.
Similar trials
Same condition (Arthritis, Rheumatoid) and phase, most recent start first.
+327 more trials See the condition page